Jacobs Levy Equity Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,641	Closed	-$249K	–	1175
2020 Q4	$249K	Sell	14,641 -172,856	-92%	-$2.17M	﹤0.01%	945
2020 Q3	$881K	Sell	187,497 -29,494	-14%	-$150K	0.01%	688
2020 Q2	$1.32M	Buy	216,991 +205,576	+1,801%	+$847K	0.01%	611
2020 Q1	$26K	Sell	11,415 -349,884	-97%	-$1.48M	﹤0.01%	991
2019 Q4	$1.66M	Buy	361,299 +240,056	+198%	+$951K	0.02%	579
2019 Q3	$470K	Buy	121,243 +82,983	+217%	+$455K	0.01%	724
2019 Q2	$231K	Sell	38,260 -29,687	-44%	-$284K	﹤0.01%	854
2019 Q1	$910K	Buy	67,947 +13,500	+25%	+$154K	0.01%	684
2018 Q4	$506K	Hold	54,447	–	–	0.01%	729
2018 Q3	$758K	Buy	54,447 +10,457	+24%	+$156K	0.01%	697
2018 Q2	$695K	Buy	43,990 +16,000	+57%	+$279K	0.01%	737
2018 Q1	$481K	Buy	27,990 +5,000	+22%	+$97.5K	0.01%	783
2017 Q4	$504K	Buy	+22,990	New	+$739K	0.01%	751

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Jacobs Levy Equity Management's FPRX Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 14,641 shares — an estimated $249K sold.

Jacobs Levy Equity Management first reported a position in FPRX in Q4 2017 and held it in 13 quarters. The position peaked at $1.66M in Q4 2019. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

Jacobs Levy Equity Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 14,641 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $249K.
Jacobs Levy Equity Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 13 quarters.
Jacobs Levy Equity Management's Five Prime Therapeutics, Inc. position peaked at $1.66M in Q4 2019.
147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.